Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: calgranulin B inhibitors - Active Biotech

Drug Profile

Research programme: calgranulin B inhibitors - Active Biotech

Alternative Names: Inhibition of S100A9 Interactions; ISI; S100A9 Inhibition by Low molecular weight Compounds; SILC

Latest Information Update: 07 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Class Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Calgranulin B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Dec 2018 Active biotech resumes preclinical development of Calgranulin B inhibitors for Cancer in Sweden (unspecified route)
  • 16 Apr 2018 Research programme: quinoline compounds - Active Biotech is available for licensing as of 16 Apr 2018. www.activebiotech.com
  • 15 Jan 2018 Active Biotech receives patent allowance for quinoline compounds in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top